Chase Farm Hospital is trialling an innovative respiratory monitoring device to speed up the identification of patients whose condition is deteriorating.

Respiratory rate is the earliest and most sensitive indicator of a worsening condition, yet is not always easy to monitor

RespiraSense is the only device that can continually monitor respiratory rate while filtering out background 'noise' caused by walking or shifting position. This provides clinical teams with highly accurate readings enabling them spot if a patient's condition is deteriorating up to 12 hours earlier than usual. 


The RFL is one of four trusts selected from a number of applicants to work with UCLPartners on piloting the device. An eight-week set up phase has begun in Chase Farm Hospital’s surgical ward. If this is successful, the ward will carry out a full pilot, receiving a free six-month supply of the monitors.

RespiraSense has been selected for the trial by NHS England’s Innovations Accelerator, which supports the uptake and spread of proven, impactful innovations.



Fiona Morcom, clinical implementation lead said: “Early identification of deterioration is challenge for hospitals worldwide. It’s vital to improve outcomes, reduce length of stay and avoid transfers to a high dependency unit. Our task in the trial is to explore how it can be embedded in our work flows and how best to use the information it provides. We’re delighted that Chase Farm Hospital was chosen for the trial as this kind of innovation fits perfectly with our aspiration to be one of the leading digital hospitals in Europe.”

Respiratory rate is a key component of the new National Early Warning Score (NEWS2) which is set to become the standard for identifying patient deterioration in England by April 2019.